Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child–Pugh B liver function at study week 8: a retrospective analysis of the CELESTIAL randomised controlled trial

被引：0
|
作者：
Anthony B. El-Khoueiry
Tim Meyer
Ann-Lii Cheng
Lorenza Rimassa
Suvajit Sen
Steven Milwee
Robin Kate Kelley
Ghassan K. Abou-Alfa
机构：
[1] USC Norris Comprehensive Cancer Center,Department of Biomedical Sciences
[2] Royal Free Hospital,Medical Oncology and Hematology Unit
[3] University College London,undefined
[4] National Taiwan University Hospital,undefined
[5] Humanitas University,undefined
[6] Humanitas Cancer Center,undefined
[7] IRCCS Humanitas Research Hospital,undefined
[8] Exelixis,undefined
[9] Inc,undefined
[10] UCSF Helen Diller Family Comprehensive Cancer Center,undefined
[11] Memorial Sloan Kettering Cancer Center,undefined
[12] Weill Medical College at Cornell University,undefined
来源：
BMC Cancer | / 22卷
关键词：
Cabozantinib; Child–Pugh B; Hepatocellular carcinoma;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] A retrospective study on the efficacy and safety of sorafenib or lenvatinib combined with sintilimab in patients with advanced hepatocellular carcinoma.
    Zeng, Zhen
    Zhang, Linzhi
    Wu, Tong
    Cheng, Jiamin
    Chen, Yan
    Lu, Yinying
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [32] Outcomes in patients who had received sorafenib as the only prior systemic therapy in the Phase 3 CELESTIAL trial of cabozantinib versus placebo in advanced hepatocellular carcinoma
    Strasser, S. I.
    Kelley, R. K.
    Ryoo, B-Y
    Merle, P.
    Park, J-W
    Bolondi, L.
    Chan, S. L.
    Lim, H. Y.
    Baron, A.
    Knox, J.
    Cattan, S.
    Yau, T.
    Lougheed, J. C.
    Milwee, S.
    El-Khoueiry, A. B.
    Cheng, A-L
    Meyer, T.
    Abou-Alfa, G. K.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 : 21 - 22
  • [33] Efficacy and safety of nintedanib vs sorafenib in Asian patients with advanced hepatocellular carcinoma (HCC): A randomised Phase II trial
    Yen, C.
    Kim, T. Y.
    Feng, Y. H.
    Chao, Y.
    Lin, D. Y.
    Studeny, M.
    Hocke, J.
    Huang, D. C. L.
    Ryoo, B. Y.
    Cheng, A. L.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S612 - S612
  • [34] The use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis
    Chiu, Joanne
    Tang, Yuen Fong
    Yao, Tzy-Jyun
    Wong, Ashley
    Wong, Hilda
    Leung, Roland
    Chan, Pierre
    Cheung, Tan To
    Chan, Albert C.
    Pang, Roberta
    Fan, Sheung-Tat
    Poon, Ronnie
    Yau, Thomas
    CANCER, 2012, 118 (21) : 5293 - 5301
  • [35] Safety and Efficacy of Lenvatinib Treatment in Child-Pugh A and B Patients with Unresectable Hepatocellular Carcinoma in Clinical Practice: A Multicenter Analysis
    Ogushi, Katsuaki
    Chuma, Makoto
    Uojima, Haruki
    Hidaka, Hisashi
    Numata, Kazushi
    Kobayashi, Satoshi
    Hirose, Shunji
    Hattori, Nobuhiro
    Fujikawa, Tomoaki
    Nakazawa, Takahide
    Wada, Naohisa
    Iwasaki, Shuichiro
    Fukushima, Taito
    Sano, Yusuke
    Ueno, Makoto
    Kawano, Kuniyuki
    Tsuruya, Kota
    Shomura, Masako
    Watanabe, Tsunamasa
    Matsunaga, Kotaro
    Kunishi, Yosuke
    Saigusa, Yusuke
    Irie, Kuniyasu
    Iwabuchi, Shogo
    Kako, Makoto
    Morimoto, Manabu
    Kagawa, Tatehiro
    Tanaka, Katsuaki
    Maeda, Shin
    CLINICAL AND EXPERIMENTAL GASTROENTEROLOGY, 2020, 13 : 385 - 396
  • [36] Real-World Efficacy and Safety of Lenvatinib in Korean Patients with Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Analysis
    Cheon, Jaekyung
    Chon, Hong Jae
    Bang, Yeonghak
    Park, Neung Hwa
    Shin, Jung Woo
    Kim, Kang Mo
    Lee, Han Chu
    Lee, Jooho
    Yoo, Changhoon
    Ryoo, Baek-Yeol
    LIVER CANCER, 2020, 9 (05) : 613 - 624
  • [37] Real-world efficacy and safety of lenvatinib in Korean patients with advanced hepatocellular carcinoma: A multicenter retrospective analysis
    Cheon, J.
    Yoo, C.
    Bang, Y.
    Chon, H.
    Ryoo, B-Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S1308 - S1308
  • [38] Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma Analysis of REACH Trial Results by Child-Pugh Score
    Zhu, Andrew X.
    Baron, Ari David
    Malfertheiner, Peter
    Kudo, Masatoshi
    Kawazoe, Seiji
    Pezet, Denis
    Weissinger, Florian
    Brandi, Giovanni
    Barone, Carlo A.
    Okusaka, Takuji
    Wada, Yoshiyuki
    Park, Joon Oh
    Ryoo, Baek-Yeol
    Cho, Jae Yong
    Chung, Hyun Cheol
    Li, Chung-Pin
    Yen, Chia-Jui
    Lee, Kuan-Der
    Chang, Shao-Chun
    Yang, Ling
    Abada, Paolo B.
    Chau, Ian
    JAMA ONCOLOGY, 2017, 3 (02) : 235 - 243
  • [39] Efficacy and Safety of Lenvatinib for Patients With Advanced Hepatocellular Carcinoma: A Retrospective, Real-world Study Conducted in Japan
    Shimozato, Naotaka
    Namisaki, Tadashi
    Okano, Akihiro
    Ohana, Masaya
    Kinoshita, Daisuke
    Kawasaki, Toshihiko
    Aihara, Yosuke
    Nakatani, Toshiya
    Kinoshita, Hiroki
    Ann, Tatsuichi
    Saito, Ko
    Yoshida, Motoyuki
    Yoshiji, Hitoshi
    ANTICANCER RESEARCH, 2022, 42 (01) : 173 - 183
  • [40] Efficacy and safety of lenvatinib for patients with advanced hepatocellular carcinoma: A retrospective, real-world study conducted in China
    Wang, Dong-Xu
    Yang, Xu
    Lin, Jian-Zhen
    Bai, Yi
    Long, Jun-Yu
    Yang, Xiao-Bo
    Seery, Samuel
    Zhao, Hai-Tao
    WORLD JOURNAL OF GASTROENTEROLOGY, 2020, 26 (30) : 4465 - 4478
12345